Other Health

Summit Healthcare Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing July 30, 2021

Tuesday, July 27, 2021 - 1:00pm

Summit Healthcare Acquisition Corp. (the Company) announced today that, commencing July 30, 2021, holders of the units sold in the Companys initial public offering of 20,000,000 units, completed on June 11, 2021, may elect to separately trade the shares of Class A ordinary shares and warrants included in the units.

Key Points: 
  • Summit Healthcare Acquisition Corp. (the Company) announced today that, commencing July 30, 2021, holders of the units sold in the Companys initial public offering of 20,000,000 units, completed on June 11, 2021, may elect to separately trade the shares of Class A ordinary shares and warrants included in the units.
  • No fractional warrants will be issued upon separation of the units and only whole warrants will trade.
  • Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Companys transfer agent, in order to separate the units into Class A ordinary shares and warrants.
  • Summit Healthcare Acquisition Corp. was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Infinity Pharmaceuticals Presents Updated Data from Phase 2 MARIO-275 Trial in Urothelial Cancer (UC) and Phase 2 MARIO-3 Trial in Triple Negative Breast Cancer (TNBC)

Tuesday, July 27, 2021 - 12:31pm

These data provide preliminary, but compelling evidence of eganelisibs potential to improve outcomes for patients with these two types of cancer.

Key Points: 
  • These data provide preliminary, but compelling evidence of eganelisibs potential to improve outcomes for patients with these two types of cancer.
  • These results are consistent with the results from MARIO-275, which show the similar translation of disease control into a meaningful survival benefit for patients.
  • For patients with TNBC, the potential to extend progression free survival, regardless of PD-L1 status, would be a transformational breakthrough.
  • MARIO-275 is a global, randomized, controlled combination study of eganelisib combined with Opdivo in I/O nave urothelial cancer.

Flora Growth to Partner with Avaria to Distribute Award-Winning Pain Cream Brand KaLaya Across LATAM & Produce Its CBD Formulations

Tuesday, July 27, 2021 - 12:05pm

Through the JV, Flora Growth will manage registration, sales, and distribution of KaLaya products in Colombia, Mexico, and other LATAM countries, while Avaria will supply finished product to the JV.

Key Points: 
  • Through the JV, Flora Growth will manage registration, sales, and distribution of KaLaya products in Colombia, Mexico, and other LATAM countries, while Avaria will supply finished product to the JV.
  • These products are expected to be distributed across LATAM using Flora Labs established distribution channels, with the aim of exporting to the U.S. market, where Avaria is currently launching the KaLaya brand.
  • Avaria does not currently hold a license in Canada to produce cannabis derived versions of its products at a commercial scale.
  • Avarias KaLaya pain cream brand has enjoyed strong success since inception, where it enjoys three consecutive years of triple digit growth through their industry leading Canadian e-commerce channels.

careNext Launches Doc360°, Consumers’ Source of Truth for Grading Providers

Tuesday, July 27, 2021 - 12:27pm

Some providers have also had the mindset that if I make you well, I dont need to make you happy.

Key Points: 
  • Some providers have also had the mindset that if I make you well, I dont need to make you happy.
  • Implementing a novel approach to grading doctors, Doc360 develops provider scores by sourcing and aggregating physician ratings from multiple web sources.
  • It is available at no cost to consumers or providers, and it eliminates score gaming by providers, which includes the ability to pay to influence ratings and the ability of competitors to negatively influence providers scores.
  • This pay to play model perversely promotes a false sense of quality, which takes direct advantage of care consumers.

Biodesix to Report Second Quarter 2021 Financial Results on August 10, 2021

Tuesday, July 27, 2021 - 11:00am

Biodesix is the first company to offer seven non-invasive tests for patients with diseases of the lung, including three proteomic tests.

Key Points: 
  • Biodesix is the first company to offer seven non-invasive tests for patients with diseases of the lung, including three proteomic tests.
  • The antibody tests can detect antibodies that are generated both from infection by the virus and from the vaccines.
  • Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors.
  • Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law.

Insights on the Flexible and Semi-Rigid Ureteroscopy Global Market to 2027 - Featuring Boston Scientific, Olympus and Stryker Among Others - ResearchAndMarkets.com

Tuesday, July 27, 2021 - 9:38am

The "Flexible and Semi-Rigid Ureteroscopy - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Flexible and Semi-Rigid Ureteroscopy - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Flexible and Semi-Rigid Ureteroscopy estimated at US$844.7 Million in the year 2020, is projected to reach a revised size of US$1.2 Billion by 2027, growing at a CAGR of 4.9% over the period 2020-2027.
  • Flexible, one of the segments analyzed in the report, is projected to record 5.6% CAGR and reach US$872 Million by the end of the analysis period.
  • The U.S. Market is Estimated at $227.8 Million, While China is Forecast to Grow at 8.1% CAGR
    The Flexible and Semi-Rigid Ureteroscopy market in the U.S. is estimated at US$227.8 Million in the year 2020.

 Purdue Pharma L.P. Announces Preliminary Voting Results on Plan of Reorganization

Tuesday, July 27, 2021 - 5:05am

Purdue Pharma L.P. today announced preliminary voting results that show overwhelming support for its chapter 11 plan of reorganization (The Plan).

Key Points: 
  • Purdue Pharma L.P. today announced preliminary voting results that show overwhelming support for its chapter 11 plan of reorganization (The Plan).
  • Out of almost 5,000 state and local governmental creditors, almost 97% voted to accept the plan.
  • The preliminary voting results demonstrate a broad consensus among every organized creditor group in these proceedings, and we will continue to work for even greater consensus ahead of the confirmation hearings.
  • Purdue expects to make public the final voting results by August 2, but the tally is not expected to change materially from these preliminary results.

Hebrew SeniorLife Makes COVID-19 Vaccination a Condition of Employment

Monday, July 26, 2021 - 11:13pm

Starting today, all new hires will be required to have a vaccination before their start date.

Key Points: 
  • Starting today, all new hires will be required to have a vaccination before their start date.
  • Lou Woolf, Hebrew SeniorLife President and CEO said, Hebrew SeniorLifes commitment is to help every senior live their best lives.
  • Hebrew SeniorLife cares for more than 3,000 seniors a day across six campuses throughout Greater Boston.
  • For more information about Hebrew SeniorLife, visit https://www.hebrewseniorlife.org or follow us on our blog , Facebook , Instagram , Twitter , and LinkedIn .

ERS Genomics and Japan SLC Sign CRISPR/Cas9 License Agreement

Tuesday, July 27, 2021 - 2:00am

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Japan SLC, Inc., a biotechnology company providing animal models to the research community, today announced a non-exclusive license agreement granting Japan SLC access to ERS Genomics CRISPR/Cas9 patent portfolio.

Key Points: 
  • ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Japan SLC, Inc., a biotechnology company providing animal models to the research community, today announced a non-exclusive license agreement granting Japan SLC access to ERS Genomics CRISPR/Cas9 patent portfolio.
  • We are proud to add Japan SLC to our growing list of partners in Japan applying CRISPR/Cas9 technology to its service offerings, said Eric Rhodes, CEO of ERS Genomics.
  • Japan SLCs animal production and supply are of high quality, and we are very pleased that it has chosen to license CRISPR/Cas9 technology through ERS Genomics.
  • We are very excited to sign this licensing agreement with ERS Genomics which will enable us to produce CRISPR-edited mouse and rat models.

Adagio Therapeutics Partners with Biocon Biologics to Bring Potent and Broadly Neutralizing COVID-19 Antibody Treatment to Patients in India and Select Emerging Markets

Monday, July 26, 2021 - 9:05pm

Biocon Biologics Ltd. is a fully integrated biosimilars company and a subsidiary of Biocon Ltd., a global biopharmaceuticals company, (BSE code: 532523, NSE: BIOCON).

Key Points: 
  • Biocon Biologics Ltd. is a fully integrated biosimilars company and a subsidiary of Biocon Ltd., a global biopharmaceuticals company, (BSE code: 532523, NSE: BIOCON).
  • Under the terms of the agreement, Adagio will provide Biocon with materials and know-how to manufacture and commercialize an antibody treatment based on ADG20 in India and additional select emerging markets.
  • ADG20, Adagios lead product candidate, is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 as either a single or combination agent.
  • The partnership provides Biocon rights to manufacture and commercialize an antibody treatment in India and additional select emerging markets based on the commercial process developed for ADG20.